The peptide field guide.

A synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) modeled on a pineal-gland extract, studied for telomerase activity and circadian rhythm.

A naturally occurring copper-binding tripeptide found in plasma, with well-studied topical cosmetic use; injectable use is investigational.

A mitochondrial-derived peptide involved in cellular energy signaling; most evidence is animal and cell, with early human trials.

A mixture of low-molecular-weight peptides derived from porcine brain, used in several countries for stroke and dementia care.

Delta sleep-inducing peptide, a nine-amino-acid neuropeptide studied for sleep architecture and stress hormones.

Nicotinamide adenine dinucleotide, a coenzyme in every cell, central to energy metabolism and DNA-repair enzymes. Offered at AMS by IV and injection.

A three-amino-acid synthetic peptide (Glu-Asp-Arg) from the bioregulator research tradition, studied for neuronal gene expression.

A synthetic analog of the immune peptide tuftsin, approved in Russia as an anti-anxiety nasal spray.

A synthetic fragment of the hormone ACTH, approved in Russia as a nasal spray for cognitive and neurological indications.

A 15-amino-acid fragment of a protein in gastric juice, extensively studied in animals for tendon, ligament, muscle, and gut-lining healing.

A three-amino-acid fragment (Lys-Pro-Val) of alpha-MSH, studied for anti-inflammatory activity in the gut and skin.

The only human cathelicidin antimicrobial peptide, part of innate immune defense; studied for infection and wound healing.

A mitochondria-targeting peptide that binds cardiolipin in the inner mitochondrial membrane, studied in formal trials for rare mitochondrial diseases and heart failure.

A naturally occurring thymus peptide that modulates immune cell activity; approved in more than 30 countries for hepatitis B and as a vaccine adjuvant.

A synthetic fragment of thymosin beta-4, a protein involved in cell migration and actin regulation, studied in animals for wound, tendon, and heart-tissue repair.

A synthetic GHRH analog that prompts the pituitary to release growth hormone. The no-DAC form is short-acting; DAC is long-acting.

A selective growth-hormone secretagogue that prompts a GH pulse with little effect on cortisol or appetite hormones.

A modified, longer-acting form of insulin-like growth factor 1, the hormone that mediates many of growth hormone's effects. Carries meaningful risk.

A natural neuropeptide at the top of the reproductive hormone cascade, triggering GnRH and therefore LH and FSH release.

A neuropeptide hormone made in the hypothalamus, often called the bonding hormone. Used for connection, mood, and sexual wellness as a nasal spray or sublingual.

A melanocortin-receptor peptide (the active ingredient in Vyleesi) that works on desire and arousal through the nervous system rather than blood flow, for men and women.

A synthetic fragment of GHRH that stimulates the pituitary's own growth-hormone release rather than replacing it with synthetic HGH.

A GHRH analog (the active ingredient in Egrifta), the most-studied peptide for visceral (deep abdominal) fat and the growth hormone axis.

A modified fragment of the growth hormone molecule (amino acids 177-191) studied for fat metabolism without growth-hormone effects on blood sugar.

A long-acting amylin analog in late-stage development, studied alone and with semaglutide (CagriSema) for appetite and weight.

A once-weekly GLP-1 receptor agonist that mimics a gut fullness hormone. FDA-approved brand products exist (Wegovy, Ozempic); offered at AMS as a physician-supervised program.

A once-weekly dual GLP-1 and GIP receptor agonist. FDA-approved brand products exist (Zepbound, Mounjaro); offered at AMS as a physician-supervised program.

A triple GLP-1, GIP, and glucagon receptor agonist in phase 3 trials, studied for weight, glucose handling, and liver fat.

A dual GLP-1 and glucagon receptor agonist in phase 3 trials for weight management and fatty liver disease.

A dual GLP-1 and glucagon receptor agonist in phase 3 trials, studied for weight and type 2 diabetes.

A small molecule (not a peptide, but often grouped with them) that inhibits the enzyme NNMT, studied in animals for fat-cell metabolism.

BPC-157 plus TB-500 in one vial: local and system-wide recovery signals together.

CJC-1295 plus ipamorelin, the most common GH pairing: a sustained GHRH baseline with a clean secretagogue pulse.

Tesamorelin plus ipamorelin: the visceral-fat GHRH analog with a selective GH pulse.

Tesamorelin, ipamorelin, and MGF (mechano growth factor, an IGF-1 splice variant studied in muscle repair).

Adds GHRP-2, an older GH-releasing peptide that also raises appetite, to the Sculpt combination.

GHK-Cu with BPC-157 and TB-500: the copper skin peptide plus both recovery peptides.

The Glow combination plus KPV for gut and inflammation.